Variables | BSI with MDR GNB, case = 109, control = 109 | BSI with MRSA, case = 67, control = 67 | ||||||
---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
OR (95% CI) | P value | AOR (95% CI) | P value | OR (95% CI) | P value | AOR (95% CI) | P value | |
Age, years | 0.99 (0.97-1.00) | 0.045a | 0.98 (0.96-1.00) | 0.03 | 1.02 (1.00-1.04) | 0.061a | ||
Female | 1.05 (0.58-1.91) | 0.88 | 0.66 (0.31-1.41) | 0.29 | ||||
Low risk BSI sourcesb | 1.29 (0.73-2.27) | 0.39 | 1.71 (0.83-3.49) | 0.15 | ||||
Invasive device in-situ | 3.43 (1.48-7.96) | 0.004a | 5.50 (1.90-15.96) | 0.002a | ||||
Indwelling catheter | 2.60 (0.93-7.29) | 0.07 | 11.00 (1.42-85.20) | 0.02 | ||||
Vascular catheter | 3.25 (1.06-9.97) | 0.04 | 2.50 (0.78-7.97) | 0.12 | ||||
Friedman et al. HCA risk factors | 4.90 (2.48-9.67) | <0.001 | 13.17 (4.07-42.59) | <0.001 | ||||
Prior hospitalisation (≥2d) last 90d | 4.50 (2.27-8.93) | <0.001a | 4.75 (2.31-9.75) | <0.001a | 5.87 (1.37-25.21) | 0.02 | ||
Residence in long-term care facilities | 2.44 (1.13-5.31) | 0.024a | 5.56 (1.60-19.34) | <0.01 | 3.78 (1.53-9.33) | 0.004a | 12.38 (2.45-62.63) | <0.01 |
Home intravenous last 30d | 8.00 (1.84-34.79) | 0.006a | 8.33 (1.52-45.75) | 0.02 | 1.67 (0.61-4.59) | 0.32 | ||
Home wound care last 30d | 1.67 (0.40-6.97) | 0.48 | 13.94 (3.31-58.68) | <0.001a | 6.74 (1.06-42.70) | 0.04 | ||
Haemodialysis last 30d | 1.50 (0.25-8.98) | 0.66 | 0.22 (0.05-1.03) | 0.054a | ||||
Intravenous chemotherapy last 30d | 2.86 (1.29-6.43) | 0.010a | 1.75 (0.51-5.98) | 0.37 | ||||
Underlying immunosuppression | 3.09 (1.57-6.10) | 0.001a | 6.67 (1.98-22.44) | 0.002a | 7.21 (1.20-43.43) | 0.03 | ||
Neutropenia | 2.57 (1.07-6.16) | 0.03 | 2.00 (0.37-10.92) | 0.42 | ||||
Active or metastatic cancer | 2.25 (1.14-4.44) | 0.02 | 1.80 (0.60-5.37) | 0.29 | ||||
Surgery last 30d | 6.50 (1.47-28.80) | 0.014a | 9.50 (2.21-40.79) | 0.002a | ||||
Presence of BSI last 3mo | 6.00 (1.77-20.37) | 0.004a | 6.50 (1.47-28.80) | 0.014a | ||||
Prior antibiotic exposure last 3mo | 8.29 (3.78-18.15) | <0.001a | 7.94 (3.36-18.80) | <0.001 | 6.76 (2.87-15.92) | <0.001a | ||
Diabetic | 1.91 (0.92-3.96) | 0.082a | 1.75 (0.73-4.17) | 0.21 | ||||
Malignancy | 1.81 (1.06-3.08) | 0.029a | 1.30 (0.57-2.97) | 0.53 | ||||
Charlson co-morbidity index | 1.16 (1.04-1.30) | 0.007a | 1.38 (1.15-1.67) | 0.001a | ||||
Intravenous drug user, IVDU | NA | NA | 0.07 (0.01-0.51) | 0.009a |